Liverpool Skyline

Public Health Institute

Prof Vivian Hope

Prof Vivian Hope

Telephone: 0151 231 4332

Biography

Viv joined the Public Health Institute in November 2016 as Professor of Public Health. Prior to that Viv was a Principal Scientist at Public Health England and also a Senior Lecturer at London School of Hygiene and Tropical Medicine. He has also held positions at Imperial College London and the University of Birmingham.

The focus of Viv’s work has been on the health harms, particularly infections, associated with drug use and sexual health. His other interests include homelessness and LGBT health.

Degrees

University of Bath, Bath, United Kingdom, PhD
University of Birmingham, Birmingham, United Kingdom, MMedSci
Royal Holloway University of London, Egham, United Kingdom, BSc (Hons)

Publications

Highlighted publications

Hope VD, Cullen KJ, Smith J, Jessop L, Parry J, Ncube F. 2016. Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection? Euro Surveill, 21 >DOI >Link

Hope VD, Harris R, McVeigh J, Cullen KJ, Smith J, Parry JV, DeAngelis D, Ncube F. 2016. Risk of HIV and hepatitis B and C over time among men who inject image and performance enhancing drugs in England and Wales: Results from cross-sectional prevalence surveys, 1992-2013 Journal of Acquired Immune Deficiency Syndromes, 71 :331-337 >DOI

Hope VD, Harris RJ, De Angelis D, Croxford S, Marongiu A, Parry JV, Ncube F. 2014. Two decades of successes and failures in controlling the transmission of HIV through injecting drug use in England and Wales, 1990 to 2011 Eurosurveillance, 19 >DOI

Hope VD, Palmateer N, Wiessing L, Marongiu A, White J, Ncube F, Goldberg D. 2012. A decade of spore-forming bacterial infections among European injecting drug users: pronounced regional variation. Am J Public Health, 102 :122-125 >DOI >Link

Marongiu A, Hope VD, Parry JV, Ncube F. 2012. Male IDUs who have sex with men in England, Wales and Northern Ireland: are they at greater risk of bloodborne virus infection and harm than those who only have sex with women? Sex Transm Infect, 88 :456-461 >DOI >Link

Dubois-Arber F, Jeannin A, Spencer B, Gervasoni J-P, Graz B, Elford J, Hope V, Lert F, Ward H, Haour-Knipe M, Low N, van de Laar M. 2010. Mapping HIV/STI behavioural surveillance in Europe. BMC Infect Dis, 10 :290 >DOI >Link

Hope V, Kimber J, Vickerman P, Hickman M, Ncube F. 2008. Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis, 8 :120 >DOI >Link

Rhodes T, Stoneman A, Hope V, Hunt N, Martin A, Judd A. 2006. Groin injecting in the context of crack cocaine and homelessness: From 'risk boundary' to 'acceptable risk'? International Journal of Drug Policy, 17 :164-170 >DOI

Hickman M, Higgins V, Hope V, Bellis M, Tilling K, Walker A, Henry J. 2004. Injecting drug use in Brighton, Liverpool, and London: Best estimates of prevalence and coverage of public health indicators Journal of Epidemiology and Community Health, 58 :766-771 >DOI

Hope VD, Rogers PA, Jordan L, Paine TC, Barnett S, Parry JV, Gill ON. 2002. Sustained increase in the sharing of needles and syringes among drug users in England and Wales. AIDS, 16 :2494-2496 >DOI >Link

Hope VD, MacArthur C, Mullis D, Radcliffe K. 2000. Relation between information and advice provision to male GUM clinic attendees and sexual orientation and ethnic group. Sex Transm Infect, 76 :198-202 >Link

Hope VD, MacArthur C. 1998. Safer sex and social class: findings from a study of men using the 'gay scene' in the West Midlands region of the United Kingdom. AIDS Care, 10 :81-88 >DOI >Link

Journal Articles

Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Bruneau J, Hickman M. 2017. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs Cochrane Database of Systematic Reviews, 2017 >DOI

Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Bruneau J, Hickman M. 2017. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction, >DOI >Link

Glass R, Hope VD, Tanner C, Desai M. 2017. 'Slamming' among men who have sex with men accessing general drug services, in response to Schmidt, AJ et al., 2016, Illicit drug use among gay and bisexual men in 44 cities: Findings from the European MSM Internet Survey (EMIS). Int J Drug Policy, 49 :24-25 >DOI >Link

Hope VD, McVeigh J, Smith J, Glass R, Njoroge J, Tanner C, Parry JV, Ncube F, Desai M. 2017. Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012-15 Drug and Alcohol Dependence, 179 :83-86 >DOI

Lewer D, Harris M, Hope V. 2017. Opiate injection–associated skin, soft tissue, and vascular infections, England, UK, 1997–2016 Emerging Infectious Diseases, 23 :1400-1403 >DOI

O'Halloran C, Cullen K, Njoroge J, Jessop L, Smith J, Hope V, Ncube F. 2017. The extent of and factors associated with self-reported overdose and self-reported receipt of naloxone among people who inject drugs (PWID) in England, Wales and Northern Ireland. Int J Drug Policy, 46 :34-40 >DOI >Link

Hope VD, Iversen J, Cullen KJ, Parry JV, Maher L, Nucbe F. 2017. Injection into the jugular vein among people who inject drugs in the United Kingdom: Prevalence, associated factors and harms. Int J Drug Policy, 46 :28-33 >DOI >Link

Bates G, Hope V, McVeigh J. 2017. HIV among people using anabolic steroids in the United Kingdom: an overview HIV Nursing, 17 :20-23

Bundle N, Bubba L, Coelho J, Kwiatkowska R, Cloke R, King S, Rajan-Iyer J, Courtney-Pillinger M, Beck CR, Hope V, Lamagni T, Brown CS, Jermacane D, Glass R, Desai M, Gobin M, Balasegaram S, Anderson C. 2017. Ongoing outbreak of invasive and non-invasive disease due to group A Streptococcus (GAS) type emm66 among homeless and people who inject drugs in England and Wales, January to December 2016. Euro Surveill, 22 >DOI >Link

Rafia R, Dodd PJ, Brennan A, Meier PS, Hope VD, Ncube F, Byford S, Tie H, Metrebian N, Hellier J, Weaver T, Strang J. 2016. An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence Addiction, >DOI

Hope VD, Parry JV, Ncube F, Hickman M. 2016. Not in the vein: 'missed hits', subcutaneous and intramuscular injections and associated harms among people who inject psychoactive drugs in Bristol, United Kingdom. Int J Drug Policy, 28 :83-90 >DOI >Link

Platt L, Reed J, Minozzi S, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Hickman M. 2016. Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs Cochrane Database of Systematic Reviews, 2016 >DOI

Hope VD, Cullen KJ, Smith J, Jessop L, Parry J, Ncube F. 2016. Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection? Euro Surveill, 21 >DOI >Link

Iversen J, Hope VD, McVeigh J. 2016. Access to needle and syringe programs by people who inject image and performance enhancing drugs International Journal of Drug Policy, 31 :199-200 >DOI

Hope VD, Harris R, McVeigh J, Cullen KJ, Smith J, Parry JV, DeAngelis D, Ncube F. 2016. Risk of HIV and hepatitis B and C over time among men who inject image and performance enhancing drugs in England and Wales: Results from cross-sectional prevalence surveys, 1992-2013 Journal of Acquired Immune Deficiency Syndromes, 71 :331-337 >DOI

Hope VD, Ncube F, Parry JV, Hickman M. 2015. Healthcare seeking and hospital admissions by people who inject drugs in response to symptoms of injection site infections or injuries in three urban areas of England. Epidemiol Infect, 143 :120-131 >DOI >Link

Cullen KJ, Hope VD, Croxford S, Shute J, Ncube F, Parry JV. 2015. Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey. Epidemiol Infect, 143 :1398-1407 >DOI >Link

Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M. 2015. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat, 22 :399-408 >DOI >Link

Croxford S, Platt L, Hope VD, Cullen KJ, Parry JV, Ncube F. 2015. Sex work amongst people who inject drugs in England, Wales and Northern Ireland: findings from a National Survey of Health Harms and Behaviours. Int J Drug Policy, 26 :429-433 >DOI >Link

Hope VD, Mandal S, Cullen KJ, Balogun K, Ncube F. 2015. Hepatitis B vaccination for people who inject drugs. Lancet, 385 :115-116 >DOI >Link

Hope VD, Scott J, Cullen KJ, Parry JV, Ncube F, Hickman M. 2015. Going into the groin: Injection into the femoral vein among people who inject drugs in three urban areas of England. Drug Alcohol Depend, 152 :239-245 >DOI >Link

Hope VD, Mcveigh J, Marongiu A, Evans-Brown M, Smith J, Kimergård A, Parry JV, Ncube F. 2015. Injection site infections and injuries in men who inject image- and performance-enhancing drugs: Prevalence, risks factors, and healthcare seeking Epidemiology and Infection, 143 :132-140 >DOI

Hope VD, Eramova I, Capurro D, Donoghoe MC. 2014. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect, 142 :270-286 >DOI >Link

MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, Taylor A, Roy K, Aspinall E, Goldberg D, Rhodes T, Hedrich D, Salminen M, Hickman M, Hutchinson SJ. 2014. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy, 25 :34-52 >DOI >Link

Hope VD, Hickman M, Parry JV, Ncube F. 2014. Factors associated with recent symptoms of an injection site infection or injury among people who inject drugs in three English cities. Int J Drug Policy, 25 :303-307 >DOI >Link

Hope VD, Harris RJ, De Angelis D, Croxford S, Marongiu A, Parry JV, Ncube F. 2014. Two decades of successes and failures in controlling the transmission of HIV through injecting drug use in England and Wales, 1990 to 2011 Eurosurveillance, 19 >DOI

Hope VD, Cullen KJ, Croxford S, Parry JV, Ncube F. 2014. Factors associated with the use of cleaned needles and syringes among people who inject drugs in the UK: who should we target to minimise the risks? Int J Drug Policy, 25 :924-927 >DOI >Link

Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, EMCDDA DRID group , Hatzakis A, Prins M, Vickerman P, Lazarus JV, Hope VD, Matheï C. 2014. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One, 9 :e103345 >DOI >Link

Palmateer NE, Hope VD, Roy K, Marongiu A, White JM, Grant KA, Ramsay CN, Goldberg DJ, Ncube F. 2013. Infections with spore-forming bacteria in persons who inject drugs, 2000-2009. Emerg Infect Dis, 19 :29-34 >DOI >Link

Vickerman P, Martin NK, Roy A, Beattie T, Jarlais DD, Strathdee S, Wiessing L, Hickman M, EMCDDA Collaborative Group . 2013. Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Depend, 132 :172-181 >DOI >Link

Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L, Hope V, de laar MV. 2013. Human immunodeficiency virus among people who inject drugs: Is risk increasing in Europe? Eurosurveillance, 18 :7-12 >Link

Platt L, Jolley E, Rhodes T, Hope V, Latypov A, Reynolds L, Wilson D. 2013. Factors mediating HIV risk among female sex workers in Europe: a systematic review and ecological analysis. BMJ Open, 3 >DOI >Link

Hope V, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergard A, Croxford S, Beynon C, Parry J, Bellis PM, Ncube F. 2013. Prevalence of, and risk factors for, human immunodeficiency virus, hepatitis B and hepatitis C infections among men who inject image- and performance-enhancing drugs in England & Wales HIV MEDICINE, 14 :2-2 >Link

Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergård A, Croxford S, Beynon CM, Parry JV, Al Bellis M, Ncube F. 2013. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: A cross-sectional study BMJ Open, 3 >DOI

Sutton AJ, House T, Hope VD, Ncube F, Wiessing L, Kretzschmar M. 2012. Modelling HIV in the injecting drug user population and the male homosexual population in a developed country context. Epidemics, 4 :48-56 >DOI >Link

Mills HL, Colijn C, Vickerman P, Leslie D, Hope V, Hickman M. 2012. Respondent driven sampling and community structure in a population of injecting drug users, Bristol, UK. Drug Alcohol Depend, 126 :324-332 >DOI >Link

Harris RJ, Ramsay M, Hope VD, Brant L, Hickman M, Foster GR, De Angelis D. 2012. Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health, 22 :187-192 >DOI >Link

Harris RJ, Hope VD, Morongiu A, Hickman M, Ncube F, DE Angelis D. 2012. Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services. Epidemiol Infect, 140 :1054-1063 >DOI >Link

Hope VD, Palmateer N, Wiessing L, Marongiu A, White J, Ncube F, Goldberg D. 2012. A decade of spore-forming bacterial infections among European injecting drug users: pronounced regional variation. Am J Public Health, 102 :122-125 >DOI >Link

Hope V, Parry JV, Marongui A, Ncube F. 2012. Hepatitis C infection among recent initiates to injecting in England 2000-2008: Is a national hepatitis C action plan making a difference? J Viral Hepat, 19 :55-64 >DOI >Link

Marongiu A, Hope VD, Parry JV, Ncube F. 2012. Male IDUs who have sex with men in England, Wales and Northern Ireland: are they at greater risk of bloodborne virus infection and harm than those who only have sex with women? Sex Transm Infect, 88 :456-461 >DOI >Link

Jolley E, Rhodes T, Platt L, Hope V, Latypov A, Donoghoe M, Wilson D. 2012. HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. BMJ Open, 2 >DOI >Link

Turner KME, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, May M, Taylor A, De Angelis D, Cameron S, Parry J, Lyons M, Goldberg D, Allen E, Hickman M. 2011. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction, 106 :1978-1988 >DOI >Link

Hope VD, Hickman M, Ngui SL, Jones S, Telfer M, Bizzarri M, Ncube F, Parry JV. 2011. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat, 18 :262-270 >DOI >Link

Hope V, Jeannin A, Spencer B, Gervasoni JP, van de Laar MJ, Dubois-Arber F, Dubois-Arber F, Spencer B, Hope V, Elford J, Lert F, Ward H, Low N, Haour-Knipe M, Jeannin A, Gervasoni JP, Pellaz MJ, Graz B, van de Laar M. 2011. Mapping HIV-related behavioural surveillance among injecting drug users in Europe, 2008 Eurosurveillance, 16

Dubois-Arber F, Jeannin A, Spencer B, Gervasoni J-P, Graz B, Elford J, Hope V, Lert F, Ward H, Haour-Knipe M, Low N, van de Laar M. 2010. Mapping HIV/STI behavioural surveillance in Europe. BMC Infect Dis, 10 :290 >DOI >Link

Presanis AM, Gill ON, Chadborn TR, Hill C, Hope V, Logan L, Rice BD, Delpech VC, Ades AE, De Angelis D. 2010. Insights into the rise in HIV infections, 2001 to 2008: a Bayesian synthesis of prevalence evidence. AIDS, 24 :2849-2858 >DOI >Link

Hope VD, Marongiu A, Parry JV, Ncube F. 2010. The extent of injection site infection in injecting drug users: findings from a national surveillance study. Epidemiol Infect, 138 :1510-1518 >DOI >Link

Elford J, Jeannin A, Spencer B, Gervasoni JP, van de Laar MJ, Dubois-Arber F, HIV and STI Behavioural Surveillance Mapping Group . 2009. HIV and STI behavioural surveillance among men who have sex with men in Europe. Euro Surveill, 14 >Link

Sweeting MJ, Hope VD, Hickman M, Parry JV, Ncube F, Ramsay ME, De Angelis D. 2009. Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again? Am J Epidemiol, 170 :352-360 >DOI >Link

Hickman M, Hope V, Coleman B, Parry J, Telfer M, Twigger J, Irish C, Macleod J, Annett H. 2009. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health (Oxf), 31 :374-382 >DOI >Link

De Angelis D, Sweeting M, Ades A, Hickman M, Hope V, Ramsay M. 2009. An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales. Stat Methods Med Res, 18 :361-379 >DOI >Link

Hickman M, McDonald T, Judd A, Nichols T, Hope V, Skidmore S, Parry JV. 2008. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat, 15 :250-254 >DOI >Link

Sutton AJ, Hope VD, Mathei C, Mravcik V, Sebakova H, Vallejo F, Suligoi B, Brugal MT, Ncube F, Wiessing L, Kretzschmar M. 2008. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study. J Viral Hepat, 15 :809-816 >DOI >Link

Hope V, Kimber J, Vickerman P, Hickman M, Ncube F. 2008. Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis, 8 :120 >DOI >Link

Lamagni TL, Neal S, Keshishian C, Hope V, George R, Duckworth G, Vuopio-Varkila J, Efstratiou A. 2008. Epidemic of severe Streptococcus pyogenes infections in injecting drug users in the UK, 2003-2004. Clin Microbiol Infect, 14 :1002-1009 >DOI >Link

Judd A, Hickman M, Hope VD, Sutton AJ, Stimson GV, Ramsay ME, Gill ON, Parry JV. 2007. Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales? J Viral Hepat, 14 :584-591 >DOI >Link

Hickman M, Hope V, Brady T, Madden P, Jones S, Honor S, Holloway G, Ncube F, Parry J. 2007. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat, 14 :645-652 >DOI >Link

Hope VD, Ncube F, Hickman M, Judd A, Parry JV. 2007. Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements? J Viral Hepat, 14 :653-660 >DOI >Link

Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M. 2006. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis, 6 :93 >DOI >Link

Rhodes T, Stoneman A, Hope V, Hunt N, Martin A, Judd A. 2006. Groin injecting in the context of crack cocaine and homelessness: From 'risk boundary' to 'acceptable risk'? International Journal of Drug Policy, 17 :164-170 >DOI

Brown AE, Tomkins SE, Logan LE, Lamontagne DS, Munro HL, Hope VD, Righarts A, Blackham JE, Rice BD, Chadborn TR, Tookey PA, Parry JV, Delpech V, Gill ON, Fenton KA. 2006. Monitoring the effectiveness of HIV and STI prevention initiatives in England, Wales, and Northern Ireland: where are we now? Sex Transm Infect, 82 :4-10 >DOI >Link

Sutton AJ, Gay NJ, Edmunds WJ, Andrews NJ, Hope VD, Gilbert RL, Piper M, Gill ON. 2006. Modelling the hepatitis B vaccination programme in prisons. Epidemiol Infect, 134 :231-242 >DOI >Link

Huntington S, Hope V, Hutchinson S, Goldberg D, Ncube F. 2006. Diversity of needle exchange provision in the UK: findings from a national survey. Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin., 11

Hickman M, Hope V, Platt L, Higgins V, Bellis M, Rhodes T, Taylor C, Tilling K. 2006. Estimating prevalence of injecting drug use: a comparison of multiplier and capture-recapture methods in cities in England and Russia. Drug Alcohol Rev, 25 :131-140 >DOI >Link

Hope VD, Hickman M, Tilling K. 2005. Capturing crack cocaine use: estimating the prevalence of crack cocaine use in London using capture-recapture with covariates. Addiction, 100 :1701-1708 >DOI >Link

Sutton AJ, Gay NJ, Edmunds WJ, Andrews NJ, Hope VD, Gill ON. 2005. Modelling the characteristics of the male injecting drug user population in England and Wales International Journal of Drug Policy, 16 :176-182 >DOI

Hope VD, Judd A, Hickman M, Sutton A, Stimson GV, Parry JV, Gill ON. 2005. HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. AIDS, 19 :1207-1214 >Link

Akbulut D, Dennis J, Gent M, Grant KA, Hope V, Ohai C, McLauchlin J, Mithani V, Mpamugo O, Ncube F, de Souza-Thomas L. 2005. Wound botulism in injectors of drugs: upsurge in cases in England during 2004. Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin., 10 :172-174

Hahne S, Crowcroft N, White J, Ncube F, Hope VD, de Souza L, Brett M, Roy K, Goldberg D. 2004. Ongoing outbreak of tetanus in injecting drug users in the UK Eurosurveillance, 8 >Link

Hope VD, Ncube F, Dennis J, McLauchlin J. 2004. Wound botulism: increase in cases in injecting drug users, United Kingdom, 2004 Eurosurveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin, 8 >Link

Hope VD, Gilbert G, Munro H, Ncube F, Gill ON. 2004. Improving targeted hepatitis B vaccination BMJ, 329: :1059-1059 >DOI >Link

Craine N, Walker AM, Williamson S, Brown A, Hope VD. 2004. Hepatitis B and hepatitis C seroprevalence and risk behaviour among community-recruited drug injectors in North West Wales. Communicable disease and public health / PHLS, 7 :216-219

Platt L, Hickman M, Rhodes T, Mikhailova L, Karavashkin V, Vlasov A, Tilling K, Hope V, Khutorksoy M, Renton A. 2004. The prevalence of injecting drug use in a Russian city: implications for harm reduction and coverage. Addiction, 99 :1430-1438 >DOI >Link

Hickman M, Higgins V, Hope V, Bellis M, Tilling K, Walker A, Henry J. 2004. Injecting drug use in Brighton, Liverpool, and London: Best estimates of prevalence and coverage of public health indicators Journal of Epidemiology and Community Health, 58 :766-771 >DOI

Jones JA, Salmon JE, Djuretic T, Nichols G, George RC, Gill ON, Brazier JS, Brett MM, Duerden BI, Fry NK, Hall V, Hope V, Lieftucht A, McLauchlin J, Pitcher DG, Weild A. 2002. An outbreak of serious illness and death among injecting drug users in England during 2000. J Med Microbiol, 51 :978-984 >DOI >Link

Hope VD, Rogers PA, Jordan L, Paine TC, Barnett S, Parry JV, Gill ON. 2002. Sustained increase in the sharing of needles and syringes among drug users in England and Wales. AIDS, 16 :2494-2496 >DOI >Link

Fitch C, Rhodes T, Hope V, Stimson GV, Renton A. 2002. The role of rapid assessment methods in drug use epidemiology Bulletin on Narcotics, 54 :61-72

Hope VD, Judd A, Hickman M, Lamagni T, Hunter G, Stimson GV, Jones S, Donovan L, Parry JV, Gill ON. 2001. Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working? Am J Public Health, 91 :38-42 >Link

Lamagni TL, Hope VD, Davison KL, Parry JV, Gill ON. 2001. Failure to vaccinate current injecting drug users against hepatitis B in England and Wales. Communicable disease and public health / PHLS, 4 :71-72

Hope VD, MacArthur C, Mullis D, Radcliffe K. 2000. Relation between information and advice provision to male GUM clinic attendees and sexual orientation and ethnic group. Sex Transm Infect, 76 :198-202 >Link

Lamagni TL, Davison KL, Hope VD, Luutu JW, Newham JA, Parry JV, Gill ON. 1999. Poor hepatitis B vaccine coverage in injecting drug users: England, 1995 and 1996. Communicable disease and public health / PHLS, 2 :174-177

Hope VD, MacArthur C. 1998. Safer sex and social class: findings from a study of men using the 'gay scene' in the West Midlands region of the United Kingdom. AIDS Care, 10 :81-88 >DOI >Link

Crampin AC, Lamagni TL, Hope VD, Newham JA, Lewis KM, Parry JV, Gill ON. 1998. The risk of infection with HIV and hepatitis B in individuals who inject steroids in England and Wales. Epidemiol Infect, 121 :381-386 >Link

Hope VD, MacArthur C. 1997. Acceptability of clinics for sexually transmitted diseases among users of the "gay scene" in the West Midlands Sexually Transmitted Infections, 73 :299-302 >DOI

Madden PB, Lamagni T, Hope V, Bennett D, Goldberg D. 1997. The HIV epidemic in injecting drug users. Communicable disease report. CDR review, 7

Hope VD, MacArthur C. 1996. A comparison of HIV related advice in genitourinary medicine clinics with different histories. Genitourin Med, 72 :286-289 >Link

Hope VD, MacArthur C. 1996. Accessibility of genitourinary medicine clinics. Genitourin Med, 72 :52-55 >Link

Editorials and letter to the editor

McVeigh J, Kimergård A, Bates G, Hope VD, Ncube F. 2016. Harm reduction interventions should encompass people who inject image and performance enhancing drugs BMJ (Online), 353 >DOI

Engagement & Impact

Conference organisation:

Conference name: 25th International Harm Reduction Conference, Montréal, Canada, 2017, Position: Programme Committee Member, URL: https://www.hri.global/conference-2017

Conference name: 24th International Harm Reduction Conference, Kuala Lumpur, Malaysia, 2015, Position: Programme Committee Member, URL: https://www.hri.global/conference-2015

Editorial boards:

Publication: International Journal of Drug Policy, Position: Guest Editor for the themed collection on ' Sexualised drug use: LGBT communities and beyond'., URL: http://www.ijdp.org/pb/assets/raw/Health%20Advance/journals/drupol/Call_for_papers_announcement.pdf

Publication: Hepatology, Medicine and Policy, Position: Associate Editor, URL: https://hmap.biomedcentral.com/about

External committees:

Committee name: Advisory group for the NIHR Career Development Grant: "Promoting skin & soft tissue infection care and preventing AA amyloidosis among people who inject drugs in the UK: A mixed methods study.", Organisation: LSHTM, Position: Member

Committee name: International Advisory group for the SPHERE-C Project, Organisation: ECDC / RKI, Position: Member, URL: https://www.rki.de/DE/Content/InfAZ/H/HepatitisC/SPHERE-C.html

Committee name: Image & Performance Enhancing Drugs Working Group (IPEDs), Organisation: Advisory Council on the Misuse of Drugs

Committee name: Drug-related infectious diseases (DRID) expert network, Organisation: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Position: National Expert for the UK, URL: http://www.emcdda.europa.eu/activities/drid

Other Professional Activity:

Describe the Professional Activities: I regularly review papers for a number of journals, including the International Journal of Drug Policy, EuroSurveillance, Addiction, and Drug & Alcohol Dependence.

Research Grants Awarded:

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2017 Rapid Communication on ‘Drug-related infectious diseases’, Grant value (£): €8,000

Public Health Wales, Image and performance enhancing drug use in Wales, Grant value (£): 25,000

Harm Reduction International, The global state of harm reduction funding, Grant value (£): 22,500